The Peptic Ulcers drugs in development market research report provides comprehensive information on the therapeutics under development for Peptic Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Peptic Ulcers. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Peptic Ulcers - Drugs In Development, 2024

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued products.

GlobalData tracks 30 drugs in development for Peptic Ulcers by 29 companies/universities/institutes. The top development phase for Peptic Ulcers is phase i with 16 drugs in that stage. The Peptic Ulcers pipeline has 29 drugs in development by companies and one by universities/ institutes. Some of the companies in the Peptic Ulcers pipeline products market are: Jiangsu Carephar Pharmaceutical, Hanmi Pharmaceuticals and Luoxin Pharmaceuticals Group Stock.

The key targets in the Peptic Ulcers pipeline products market include Potassium Transporting ATPase Alpha Chain 1, Prostaglandin G/H Synthase 2, and Prostaglandin G/H Synthase 1.

The key mechanisms of action in the Peptic Ulcers pipeline product include Potassium Transporting ATPase Alpha Chain 1 Inhibitor with 12 drugs in Pre-Registration. The Peptic Ulcers pipeline products include six routes of administration with the top ROA being Oral and one key molecule types in the Peptic Ulcers pipeline products market including Small Molecule.

Peptic Ulcers overview

Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach, and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes, and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotics, acid blockers, antacids, and proton pump inhibitors.

For a complete picture of Peptic Ulcers’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.